Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain

BACKGROUND: Atezolizumab has recently been approved for first-line treatment of high PD-L1 expression metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with no EGFR or ALK mutations, on the basis of the IMpower110 trial. This study aims to estimate the cost-effectiveness of atezolizumab compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Isla, Dolores, Lopez-Brea, Marta, Espinosa, María, Arrabal, Natalia, Pérez-Parente, Diego, Carcedo, David, Bernabé-Caro, Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841669/
https://www.ncbi.nlm.nih.gov/pubmed/36647072
http://dx.doi.org/10.1186/s12962-023-00417-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841669/
https://www.ncbi.nlm.nih.gov/pubmed/36647072
http://dx.doi.org/10.1186/s12962-023-00417-z

Ejemplares similares